Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.61 |
| ▸ | HTR2B | P41595 | 11/20 | 0.61 |
| ▸ | HTR2A | P28223 | 10/20 | 0.61 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015409 | 1.00 | HTR2C (0.61) | HTR2CHTR2BHTR2AKDM5APARP1 | |
| Hydrochloric Acid SCHEMBL11737591 | 0.98 | HTR2C (0.59) | HTR2CHTR2BHTR2AKDM5APARP1 | |
| SCHEMBL30169487 | 0.91 | HTR2C (0.70) | HTR2CHTR2BHTR2APARP1 | |
| SCHEMBL21040315 | 0.89 | HTR2C (0.56) | HTR2CHTR2BHTR2AKDM5ACRBN | |
| Hydrochloric Acid SCHEMBL30321070 | 0.87 | HTR2C (0.55) | HTR2CHTR2BHTR2AKDM5ACRBN | |
| SCHEMBL28985479 | 0.86 | HTR2C (0.54) | HTR2CHTR2BHTR2AKDM5A | |
| SCHEMBL7230144 | 0.84 | HTR2C (0.52) | HTR2CHTR2BHTR2A | |
| SCHEMBL1976916 | 0.84 | PARP1 (0.56) | HTR2CHTR2BHTR2AKDM5APARP1 | |
| SCHEMBL16334116 | 0.83 | HTR2B (0.67) | HTR2CHTR2BHTR2APARP1 | |
| SCHEMBL16336941 | 0.83 | HTR2B (0.67) | HTR2CHTR2BHTR2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2012025155-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
| US-4304912-A | Piperidine derivatives | CIBA-GEIGY CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| US-4029795-A | 4(2' Isoquinolin-1-one)piperidines | CIBA-GEIGY CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | HTR2C 1517/4885HTR2B 2151/4885HTR2A 1239/4885 |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HTR2C 2313/4885HTR2B 1760/4885HTR2A 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.